People have a right to receive accurate and up-to-date information about their medicines from their health professionals. Providing written and verbal medicine information can improve consumers' use of medicines, but it can also have a negative impact. Consumer medicine Information is standardised written information about prescription and pharmacistonly medicines in Australia. It is a tool which can be used by health professionals during their consultations to explain about the treatment they are recommending, including its harms and benefits. If used effectively and appropriately, Consumer medicine Information could become an important vehicle in ensuring the quality use of medicines. Although some consumers are receiving Consumer medicine Information from their health professionals, the documents are generally underutilised.
Introduction
There have been increasing demands for information about medicines from consumers who consider written information to be useful 1, 2 and have been in favour of receiving it. 3, 4 In Australia consumer organisations drove the development of Consumer Medicine Information (CMI) which is now available for all prescription medicines. Some consumers prefer to receive this information from their doctors 5 while others prefer pharmacists 3, 5 , however many health professionals have been doubtful about the value of CMI.
Research shows that there is limited interaction between consumers and health professionals when written medicine information is provided. 2, 5 This is unfortunate because, when received with verbal advice, written information has many positive impacts on consumers 6 , including improved adherence to therapy. 7, 8, 9 Medicines information specifically written for consumers should therefore have an important role in consultations and support the quality use of medicines.
What is a CmI and how is it distributed?
It is a legal requirement that CMI is available for all prescription (S4 and S8) and pharmacist-only (S3) medicines, and that it is consistent with the approved product information. The content of a CMI is defined by legislation and includes headings such as how to take your medicines, side effects and a description of the product. Australian CMIs are unique because they were developed to enable consumers to easily locate the information they need and the current design and content have been tested to ensure this. 
The consumer experience
Anecdotally, very few Australian consumers are receiving CMI with their prescription medicines. Moreover, when CMI is given, it tends not to be discussed as part of the consultation.
Those consumers who are aware of CMI, who receive it from pharmacists and who read it 5,11 , do not know how it differs from other forms of written information. 13 In a survey of 226 consumers in community pharmacies in metropolitan Sydney, 58% reported receiving CMI on the day of the interview, and 82% said that they had received CMI in the past. 5 Their main reasons for reading CMI were to gain knowledge about their medicines, and concerns about adverse effects. The most commonly cited impact of reading the CMI was being informed, followed by being more confident about the medicine and its importance. showed that 94% had received a computer-generated CMI from their pharmacist on at least one occasion. Two later telephone surveys of 1000 consumers indicated that 24% and 29% of the respondents had remembered receiving a computer-generated CMI from their pharmacist, sometime in the past. Some reported that the CMI caused them to be anxious about their medicines.
There is contradictory evidence regarding the impact of written medicine information on the adverse effects experienced by consumers who read the information. Some studies show a direct relationship between fear of adverse effects and stopping medicines after reading written information. 14, 15 Other studies have shown no relationship. 7, 16, 17 The reluctance of some health professionals to provide CMI to consumers for fear that the information can lead to perceived or actual experience of adverse effects and consequent non-adherence to therapy may not be fully justified. However, the negative impact is real and this is why it is preferable to discuss CMI with the consumer rather than just handing it out.
Although there is some discrepancy between the actual 
use by health professionals
Consumers want to receive information from their health professionals, some from their doctors 5 and others from their pharmacists. 3, 5 It is therefore in the best interests of consumers if health professionals are aware of CMI and how to use it.
The first guidelines for health professionals were published in 1995. 18 They contained recommendations on the provision of CMIs, their use in counselling about the treatment and the action to be taken in special circumstances, such as emergencies. The guidelines suggested that health professionals provide CMIs to non-English speaking people, but take reasonable steps to ensure that they understand the information 
How can a CmI be used in practice?
In using CMI with consumers (Box 1), it is important that health professionals are familiar with its structure and content. 10 It is also important to note that while areas within a CMI can be highlighted for increased consumer attention, no sections of a CMI should be deleted or crossed out as this de-emphasising of information might increase the health professional's liability should any problems occur. 12 Health professionals can increase consumer awareness of CMI by encouraging their patients to ask for CMI for their current and new medicines.
Conclusion
Consumers have a right to receive information about the medicines they are taking. Although some consumers are receiving CMI, there is a need to increase its provision. The challenge for all health professionals is to integrate the CMI into their consultations. Consumers, too, should be made aware of CMI and that they can ask for a CMI about their medicine.
There is also a need to evaluate CMI receipt and use by consumers, and to assess the impact of CMI on the healthcare system. There is an expectation that CMI will promote the quality use of medicines, but there is no evidence currently available to confirm this.
